ChemoCentryx (CCXI) – Company Press Releases
-
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
-
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
-
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
-
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
-
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
-
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
-
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
-
CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm
-
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
-
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
-
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
-
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
-
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
-
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
-
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
-
ChemoCentryx Announces Changes to its Board of Directors
-
ChemoCentryx Announces Changes to its Board of Directors
-
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
-
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
-
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
-
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
-
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
-
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
-
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
-
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
-
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Me
-
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Me
-
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, and ChemoCentryx on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
-
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
-
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
-
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
-
ChemoCentryx to Present at Two Upcoming Investor Conferences
-
ChemoCentryx to Present at Two Upcoming Investor Conferences
-
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
-
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
-
ChemoCentryx to Participate in Two Upcoming Investor Conferences
-
ChemoCentryx to Participate in Two Upcoming Investor Conferences
-
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
-
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
Back to CCXI Stock Lookup
